{
  "abstract": "Background: Targeted immunotherapies have expanded treatment options for acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG), but evidence regarding their sequencing and individualized therapeutic pathways remains limited.\n\nMethods: We describe seven selected adults with AChR-positive gMG managed through individualized targeted-treatment pathways involving administered and, in some cases, planned sequential therapy. Treatment selection was guided by disease severity, corticosteroid-related risks, presence of thymoma, comorbidities, peripheral venous access and the need for rapid clinical improvement and/or sustained disease management.\n\nResults: Across the seven cases, FcRn antagonists were used for rapid symptom control, corticosteroid dose reduction and bridging therapy while the appropriate vaccinations required before planned complement inhibition or B-cell depletion therapy were completed. Rituximab was selected as a long-term B-cell-directed immunosuppressive strategy, particularly in recent-onset gMG. Ravulizumab was planned as a long-term, non-steroidal immunosuppressive therapy in thymoma-associated myasthenia gravis and in chronic gMG with symptoms refractory to conventional non-steroidal immunosuppressive therapy and dependent on corticosteroids.\n\nConclusion: These seven cases illustrate how targeted immunotherapies may be used sequentially and individualized according to their onset of action, MG subgroup, treatment goal, required vaccinations and route of administration.",
  "abstract_shown": true,
  "affiliations": [
    "First Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens"
  ],
  "article_type": "brief report",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Vasiliki Zouvelou"
    },
    {
      "affs": [
        0
      ],
      "name": "Dimitra Tzavella"
    },
    {
      "affs": [
        0
      ],
      "name": "Eleni Strataki"
    },
    {
      "affs": [
        0
      ],
      "name": "Aigli G. Vakrakou"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8hs3wzttwa4hp.bib",
  "cited_by": 0,
  "doi": "10.3389/fneur.2026.1989043",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719606/?tool=EBI",
  "id": "8hs3wzttwa4hp",
  "issns": [
    "1664-2295"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fneur.2026.1989043/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Perspective"
    ],
    [
      "openalex",
      "2728|Myasthenia Gravis and Thymoma"
    ]
  ],
  "openalex": "W7222408328",
  "pdf_url": "https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2026.1989043/pdf",
  "pmcid": "PMC13719606",
  "pmid": "42964369",
  "published": "2026-10-16",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/8hs3wzttwa4hp.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:16Z",
      "native_id": "10.3389/fneur.2026.1989043",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fneur.2026.1989043/full"
    },
    {
      "first_seen": "2026-10-31T12:21:36Z",
      "native_id": "PMC:PMC13719606",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13719606"
    },
    {
      "first_seen": "2026-11-02T12:23:32Z",
      "native_id": "PMC13719606",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fneur.2026.1989043"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Myasthenia Gravis and Thymoma",
      "subfield": "neurology"
    }
  ],
  "title": "Individualized sequencing of targeted immunotherapies in generalized myasthenia gravis across distinct patient profiles",
  "title_text": "Individualized sequencing of targeted immunotherapies in generalized myasthenia gravis across distinct patient profiles",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:20:38Z",
  "url": "https://research.draconitic.com/paper/8hs3wzttwa4hp",
  "venue": "Frontiers in Neurology",
  "versions": []
}